【9月18日,减肥药制造商诺和诺德美股盘前涨超4%】周三,诺和诺德报告Oasis4第三阶段试验结果,每日一次口服版减肥药物Wegovy让患者平均体重减轻16.6%。 公司指出,与服安慰剂患者相比,服用Wegovy患者心血管风险因素有所改善。 公司还表示,这些结果与此前注射型Wegovy试验结果一致。本文由 AI 算法生成,仅作参考,不涉投资建议,使用风险自担本文来自和讯财经,更多精彩资讯请下载“...
Source Link【9月18日,减肥药制造商诺和诺德美股盘前涨超4%】周三,诺和诺德报告Oasis4第三阶段试验结果,每日一次口服版减肥药物Wegovy让患者平均体重减轻16.6%。 公司指出,与服安慰剂患者相比,服用Wegovy患者心血管风险因素有所改善。 公司还表示,这些结果与此前注射型Wegovy试验结果一致。本文由 AI 算法生成,仅作参考,不涉投资建议,使用风险自担本文来自和讯财经,更多精彩资讯请下载“...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.